Results 91 to 100 of about 51,741 (305)

Risk of herpes zoster following mRNA COVID-19 vaccine administration

Expert Review of Vaccines, 2023
Background Adverse events following mRNA COVID-19 vaccines, including herpes zoster (HZ), have been reported. We conducted a cohort study to evaluate the association between mRNA COVID-19 vaccination and subsequent HZ at Kaiser Permanente Southern ...
Ana Florea, Jun Wu, Lei Qian, Bruno Lewin, Lina S. Sy, I-Chun Lin, Jennifer H. Ku, Hung Fu Tseng   +7 more
doaj   +1 more source

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

Current Issues in Molecular Biology, 2022
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection.
Markus Aldén, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, Cheng Luan, Magnus Rasmussen, Yang De Marinis   +6 more
doaj   +1 more source

Heterologous vaccination of BNT162b2 in Ad26. COV2.S-vaccinated healthcare workers elicits long-term humoral immune response [PDF]

, 2022
Background. To date, there are no immunological data for the SARS-CoV-2 heterologous vaccination schedule in the South African (SA) population.Objectives.
Bekker, L-G, Gray, G, Jacobson, B, Khan, A, Mayne, E, Sanne, I, Segal, B, Shulman, A H   +7 more
core   +3 more sources

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination

Vaccines, 2022
Although serious adverse events have remained uncommon, cases of myocarditis induced by messenger RNA (mRNA) COVID-19 vaccines have been reported. Here, we presented a rare but potentially fatal disorder, hemophagocytic lymphohistiocytosis, in a 14-year-old previously healthy adolescent after BNT162b2 mRNA vaccination.
Ting-Yu Lin, Yun-Hsuan Yeh, Li-Wen Chen, Chao-Neng Cheng, Chen Chang, Jun-Neng Roan, Ching-Fen Shen   +6 more
openaire   +3 more sources

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Nature Medicine, 2021
The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in ...
T. Kustin, Noam Harel, U. Finkel, Shay Perchik, Sheri Harari, Maayan Tahor, Itamar Caspi, R. Levy, Michael Leshchinsky, Shifra Ken Dror, Galit Bergerzon, Hala Gadban, Faten Gadban, Eti Eliassian, O. Shimron, Loulou Saleh, H. Ben‐Zvi, E. Keren Taraday, D. Amichay, A. Ben-Dor, Dana Sagas, M. Strauss, Y. Shemer Avni, A. Huppert, Eldad Kepten, R. Balicer, D. Netzer, S. Ben-Shachar, A. Stern   +28 more
semanticscholar   +1 more source

Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods.
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šušteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron

iScience, 2022
Summary: Heterologous ChAdOx1-BNT162b2 vaccination induces a stronger immune response than BNT162b2-BNT162b2. Here, we investigated the molecular transcriptome, germline allelic variants of immunoglobulin loci, and anti-Omicron antibody levels in 46 ...
Hye Kyung Lee, Jinyoung Go, Heungsup Sung, Seong Who Kim, Mary Walter, Ludwig Knabl, Priscilla A. Furth, Lothar Hennighausen, Jin Won Huh   +8 more
doaj   +1 more source

Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain [PDF]

, 2021
Breastfeeding mothers were excluded from the clinical trials conducted for vaccines against SARS-CoV-2. Since the start of the vaccination, some doubts have arisen regarding its compatibility with breastfeeding.
Cabero Pérez, María Jesús, Calvo Montes, Jorge, Cuesta González, Rocío, Irure-Ventura, Juan, Lechosa Muñiz, Carolina, Llorca Díaz, Francisco Javier, López Hoyos, Marcos, Mendez-Legaza, Jose Manuel, Paz Zulueta, María   +8 more
core   +1 more source

Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study [PDF]

, 2022
The SARS-CoV-2 pandemic led to the development of various vaccines. The BNT162b2 mRNA vaccine was the first approved due to its efficacy in eliciting a humoral immunity response after the second dose. However, a decrease in the antibody concentration was
Alessandra Panico, Antonella De Donno, Antonella Zizza, Chiara Rosato, Floriano Indino, Francesco Bagordo, Giambattista Lobreglio, Michele Chicone, Pietro Alifano, Roberta Lazzari, Tiziana Grassi, Virginia Recchia   +11 more
core   +2 more sources

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine

Journal Français d'Ophtalmologie, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accelerated vaccine development. The BNT162b2 messenger RNA (mRNA) vaccine is being administered worldwide. The purpose of this case series is to report a possible association between the BNT162b2 mRNA vaccine and Central serous chorioretinopathy (CSC).
Hanhart, J., Roditi, E., Wasser, L.M., Barhoum, W., Zadok, D., Brosh, K.   +5 more
openaire   +2 more sources